Abstract. Secreted Wingless type (Wnt) ligands have previously been shown to be involved in tumor developmental processes and oncogenesis. Aberrant promoter methylation of Wnt inhibitory factor-1 (WIF-1) is a fundamental mechanism of epigenetic silencing in human cancers. Procaine, a local anesthetic drug, and procainamide, a drug for the treatment of cardiac arrhythmias, have been reported as inhibitors of DNA methylation, causing demethylation and reactivation of methylation-silenced genes such as RARß and GSTP1. The promoter demethylation of WIF-1 has not previously been reported on. We demonstrated previously that WIF-1 is silenced due to promoter hypermethylation in lung cancer cell lines. In this study, we demonstrate promoter demethylation of WIF-1; restoration of WIF-1 expression, and underexpression of cytosolic ß-catenin protein and TCF reporter activity, after procaine and procainamide treatment in H460 and A549 cell lines. Our results provide the first evidence that procaine and procainamide reactivate WIF-1 in these cancer cells and downregulate the Wnt canonical pathway. These results further suggest that procaine and procainamide may have a potential use for preventing the development of lung cancer.

Introduction

Silencing of the promoter methylation X of tumor suppressor genes is recognized as being a molecular hallmark of human cancer (1-4). Nearly 50% of all proven tumor suppressor genes can be silenced by hypermethylation along with many genes that play putative roles in antitumor activities (5).

The Wingless-type (Wnt) family of secreted glycoproteins is a group of signaling molecules that have been implicated in oncogenesis (6,7). The proto-oncogenic effects of WNT were discovered more than 20 years ago (8). Since then, there have been numerous demonstrations of aberrant Wnt signaling pathway activation in disparate human cancers including colorectal cancer (9), head and neck carcinoma (10), melanoma (11), and leukemia (12). We previously reported overexpression of disheveled (Dvl) and ß-catenin proteins in mesothelioma, nasopharyngeal carcinoma (NPC) and nonsmall cell lung cancer (NSCLC) (13-15).

Wnt inhibitory factor-1 (WIF-1) is a Wnt antagonist that inhibits Wnt signaling by direct binding to Wnt molecules. WIF-1 silencing, due to promoter hypermethylation, has been observed in NSCLC, NPC, gastrointestinal malignancies, melanoma and Barrett’s esophagus (16-18). Previously, we cloned the WIF-1 promoter in NSCLC and colorectal cancer cell lines (19).

Procaine, a drug approved by the FDA for use as a local anesthetic and procainamide, FDA approved for treatment of cardiac arrhythmias, are derivatives of 4-aminobenzoic acid. However, procaine is the ester with 2-(diethylamino)ethanol while procainamide is the amide with 2-(diethylamino)ethylamine. Procaine was previously reported to be an inhibitor of DNA methylation in breast cancer cells, causing demethylation and reactivation of tumor suppressor genes with hypermethylated CpG islands (20). Procainamide has been indicated as an inhibitor of DNA methylation, specifically causing DNA demethylation (21) and expression of GSTP1 gene in prostate cancer cells (22), and expression of ER, RARß, and p16 genes in bladder and breast cancer cells (23), where previously silenced by hypermethylation. However, the promoter demethylation of WIF-1 has not previously been reported. Herein, we hypothesize that procaine and procainamide may be used as an effective and nontoxic demethylating agents of the WIF-1 promoter.
Materials and methods

Cell lines, tissue samples and chemical treatment. NSCLC cell lines (H1703, H460, and A549) and colorectal cancer cell line HCT116 were obtained from American Type Culture Collections (Manassas, VA). Cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, penicillin (100 IU/ml), and streptomycin (100 μg/ml). All cells were cultured at 37˚C in a humid incubator with 5% CO2. Normal lung tissues from patients undergoing resection for lung cancers were collected at the time of surgery and immediately snap-frozen in liquid nitrogen (Institutional Review Board approval H8714-15319-040). These tissue samples were kept at -170˚C in a liquid nitrogen before use. Procaine, procainamide and 5-Aza-2'-deoxycytidine (DAC) was obtained from Sigma-Aldrich (St. Louis, MO, USA). They were prepared as stock solutions in dimethyl sulfoxide (DMSO), diluted in media and sterile filtered before use. To restore WIF-1 expression, 1x10^5 cells were seeded into 6-well culture plates. After 24-h culture, cells were treated with procaine, procainamide (0-1 mM) and DAC (20 μM) for 72 h, treatment and harvested as mentioned previously (24).

Cell proliferation. H460, A549, and HCT116 cells were plated in 96-well plates at a density of 5000 cells/well. Cells were allowed to attach overnight in growth medium. After 24 h, H460, A549, and HCT116 cells were treated with procaine and procainamide (0-2 mM). After incubation for 72 h, cellular proliferation was measured using the MTS assay and absorbance was measured at 490 nm. Proliferation data are presented as means ± SD.

Semiquantitative reverse transcription-PCR. Total RNA from H460, A549, HCT116, and H1703 cell lines and normal lung tissue was isolated using an extraction kit (RNeasy mini kit; Qiagen, Valencia, CA, USA). Reverse transcription-PCR (RT-PCR) was performed in Bio-RAD iCycler (Bio-RAD Laboratories, Hercules, CA, USA) using an RT-PCR kit (SuperScript One-step RT-PCR with Platinum Taq kit; Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Primer sequences for the human WIF-1 cDNA were 5'-CCGAAATGGAGGCTTTTGTA-3' (forward) and 5'-GTGTCTTCCATGCCAACCTT-3' (reverse). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control.

Figure 1. Proliferation effects of procaine and procainamide in H460, A549 and HCT116 cells (A). Cells were treated with procaine and procainamide (0-2 mM) and incubated for 72 h and proliferation was assessed by MTS assay. Experiments were performed independently at least 3 times; control carrier DMSO (0 mM). Data are the means ± SD, N and M represent procaine and procainamide, respectively. (B) Reverse transcriptase-PCR for WIF-1. The amplified human cDNA fragment is 451 bp. The H1703 and HCT116 were included as positive and negative control, respectively. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control for RNA quality and loading.
Methylation-specific PCR (MSP). Genomic DNA from the cell lines and normal lung tissue was extracted using Qiagen's DNeasy blood and tissue kit, according to the manufacturer's protocol. Bisulfite modification of genomic DNA was performed by using a methylation kit (EZDNA methylation kit; Zymo Research, Orange, CA, USA). Bisulfite-treated genomic DNA was amplified using either a methylation-specific or an unmethylation-specific primer set. HotStarTaq DNA polymerase (Qiagen) was used in the experiments. Sequences of the methylation-specific primers were 5'-TCGCGGGCGTTTTATTGGGC-3' (forward) and 5'-AACGAACCAACAATCAACG-3' (reverse). Sequences of the unmethylation-specific primers were 5'-TTGTGGGTGTATTGGGT-3' (forward) and 5'-AACAAAACCAACATCAACA-3' (reverse).

Sequencing analysis. Bisulfite-treated genomic DNA was amplified using two pairs of primers: 5'-GAGTGATGTTTTAGGGGTTT-3' (forward) and 5'-CCTAAATACCAAAAACTAC-3' (reverse), designed to amplify nucleotides -554 to -140 of the WIF-1 promoter region; and 5'-GGGTTTATTGGG-3' (forward) and 5'-TCTCATCAATACAACTCTCCTC-3' (reverse), to amplify nucleotides -161 to +118 (the start codon ATG of WIF-1 is defined as +1). The PCR products were extracted from the agarose gel using an extraction kit (Qiagen) and were subsequently sequenced at MCLab (South San Francisco, CA, USA).

Western blotting. Cytosolic proteins were prepared as previously described (26). The proteins were separated on 4-15% gradient SDS-polyacrylamide gels and transferred to Immobilon-P membranes (Millipore, Bellerica, MA, USA). The proteins were bound with the primary antibodies of β-catenin (Transduction Laboratories, Lexington, KY, USA) and β-actin (Sigma Chemical). Antigen-antibody complexes were detected by ECL blotting analysis system (Amersham Pharmacia Biotech, Piscataway, NJ, USA).

Results

Effect of procaine and procainamide on cell proliferation. We analyzed the effects of procaine and procainamide on cell proliferation in H460, A549, and HCT116 cell line using MTS assay (Fig. 1A). We compared with that of controls, the remaining cell viability was not altered at a concentration ≤1 mM and reduced at concentrations of 2 mM. Therefore, the treatment of procaine and procainamide, at the concentrations ranging from 0 to 1 mM, has no cytotoxic effects on the H460, A549, and HCT116 cells during 72-h incubation period.

Silencing and promoter methylation of WIF-1 in H460 and A549 cell lines. The methods to identify the WIF-1 promoter have been described previously (16). We confirm that the 5' region of the gene presents classical features of a promoter region and map 106 CpG islands within the WIF-1 promoter. WIF-1 expression was examined as previously described (16,27). We found that the WIF-1 transcript was missing in H460, A549, and HCT116 cell lines. In contrast, it was expressed in H1703 cells and normal lung (Fig. 1B). Promoter methylation was found by using methylation-specific PCR (MSP) in H460 and A549 cell lines (Fig. 2A). Consistent with MSP results,
we found that these CpG islands in H460 and A549 cell lines were densely methylated by using bisulfite genomic DNA sequencing technique. In contrast, CpG islands in normal lung tissue were unmethylated (Fig. 2B).

Promoter demethylation of WIF-1 gene with procaine and procainamide treatment. We analyzed the methylation status of CpG islands in the WIF-1 promoter region in H460 and A549 cell lines after incubation with procaine and procainamide (0-1 mM) for 3 days. By using MSP technique, the WIF-1 promoter region revealed concentration-dependent demethylation (Fig. 2A), DAC was used as a positive demethylation control (15). We also used bisulfite genomic DNA sequencing to analyze details of the methylation status of 64 CpG sites in the 672 bp of the WIF-1 promoter region. The sequencing results showed that the WIF-1 promoter methylation level decreased from 77.6% to 25.5% and 36.9% after treatment with 0.5 mM procaine and procainamide in H460 cell line and from 76.5% to 23.9% and 33.3% in A549 cell line (Fig. 2B).

Restoration of WIF-1 expression with procaine and procainamide treatment. Then we analyzed the expression level of WIF-1 by semiquantitative RT-PCR. In agreement with the MSP and sequencing data, the results revealed detectable and concentration-dependent reactivation after treatment by procaine for 3 days, but no concentration-dependent reactivation after treatment by procainamide (Fig. 3). These results suggest that WIF-1 silence in H460 and A549 cell lines correlates with dense methylation of WIF-1 promoter region and can be restored by procaine and procainamide.

Downregulation of the Wnt canonical pathway. Downregulation of the Wnt canonical pathway was confirmed of Tcf/Lef transcriptional activity and cytosolic β-catenin protein level. The TOP/FOP flash plasmid system was used to determine Tcf/Lef activity, the results revealed concentration-dependent decrease of TOP/FOP luciferase activity after...
treatment by procaine and procainamide (Fig. 4A). We subsequently measured expression of β-catenin by Western blot analysis using β-actin as an internal control, and found that H460 and A549 cells had slightly decreased expression of β-catenin after treatment by procaine and dramatically decreased expression by procainamide (Fig. 4B).

**Discussion**

Wnt signaling has emerged as a critical pathway in lung carcinogenesis. This has been amply demonstrated in numerous cancers (28,29). Several Wnt pathway proteins, including Wnt-1, Dvl-3 and β-catenin, have also been shown to be overexpressed in a number of cancers.

Wnt inhibitory factor-1 (WIF-1), a highly conserved gene that was first identified in the human retina, is a Wnt antagonist that inhibits Wnt signaling by direct binding to Wnt molecules. WIF-1 downregulates the Wnt pathway and inhibits NSCLC cell growth. Transfection with WIF-1 induces apoptosis in NSCLC cells and inhibits colony formation. Transfection by injecting WIF-1 plasmid also inhibits NSCLC tumor xenograft growth (16).

A growing list of genes have been identified that evidence abnormal CpG island promoter methylation (30). Methylation of the CpG island within the functional promoter region of WIF-1 is an important mechanism of aberrant Wnt signaling activation in cancer. Thus, by using methylation specific PCR and sequence analysis after bisulfite treatment, we demonstrated the frequent hypermethylation of the CpG islands in the functional WIF-1 promoter region, the hypermethylation correlated with their transcriptional silencing in human lung cancer cell lines (16). Conversely, promoter demethylation of WIF-1 restored the silenced WIF-1.

Procaine has been previously reported, in breast cancer cells, to cause global DNA hypomethylation, growth inhibition, and demethylation and re-expression of a methylation-silenced RARβ2 (20). As such, procaine behaves very similarly to procainamide, the latter which specifically inhibits the hemi-methylase activity of DNA methyltransferase 1 (DNMT1) (31), restores the expression of the hypermethylated GSTP1 gene in prostate cancer cells, and diminishes xenograft tumor growth (23). Therefore, we hypothesize that procaine and procainamide can also reactivate methylation-silenced WIF-1 gene.

In this study, we demonstrated that untreated H460 and A549 cells which were methylated silenced the expression of the WIF-1 gene. However, after exposure to procaine and procainamide, this epigenetic change was reversed. We also showed that H460 and A549 cells treated with procaine and procainamide decreased Tcf/Lef activity and expression of β-catenin using a TOP/FOP Dual-Luciferase reporter assay and Western blot analysis, respectively.

These results are consistent with our hypothesis that procaine and procainamide may, in addition to restoring the methylated WIF-1 by demethylation, downregulate the Wnt canonical pathway in H460 and A549 cell lines.

The use of the nucleoside analogs such as DAC in clinical trials has been limited due to their side effects, including thrombocytopenia and neutropenia, probably caused by cytotoxic effects associated with the incorporation of the drugs into DNA, apart from their DNA-hypomethylation value. There is thus an urgent need to discover less toxic demethylating agents that are not incorporated into DNA. Procaine and procainamide have been proposed as non-nucleoside inhibitors of DNA methylation. Their side effects are expected to be less as seen in nucleoside DNA methylation inhibitors because of their widespread clinical use (32).

We provided the first evidence that procaine and procainamide reanimate WIF-1 from a previously silenced methylation state and downregulate the canonical Wnt pathway. Procaine and procainamide may have a potential use for preventing the development of cancer.

**Acknowledgements**

This work was supported by NIH grant RO1 CA 093708-01A3, and the Larry Hall memorial trust and Bonnie J. and Anthony Addario; the Bonnie J. Addario Lung Cancer Foundation; the Eileen D. Ludwig Endowed for Thoracic Oncology Research, Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation, Inc.; Estate of Robert Griffiths; Estate of Norman Mancini; the Barbara Isackson Lung Cancer Research Fund. We thank Mr. Richard N. Barg, JD/MBA of the Thoracic Oncology Program and the Department of Surgery at the University of California, San Francisco for his editorial help in the preparation of this manuscript.

**References**


